Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Begins Data Submission for AD Med Lecanemab in China
December 26, 2022
- Eisai Issues Statement after 3rd Death Potentially Tied to Lecanemab Reported
December 26, 2022
- Shionogi JV, Shanghai Pharma Ink Xocova Import Pact in China
December 26, 2022
- Sanofi Launches Cablivi in Japan for Acquired TTP
December 26, 2022
- Opdivo-Chemo Combo Fails in Asian Adjuvant Study for Gastric Cancer
December 26, 2022
- Yescarta Gets Second-Line Nod for Large B-Cell Lymphoma in Japan
December 26, 2022
- PeptiDream, US Merck Strike Deal on PDC Development
December 23, 2022
- Kaken Subsidiary Hits PII Goal for Vascular Malformation Drug
December 23, 2022
- Janssen Labor Union to Hold 1st Bargaining Session as Early as Jan. 11
December 23, 2022
- Takeda, Mitsubishi, IIF to Operate Shonan iPark under New Joint Firm
December 22, 2022
- Genmab Files Epcoritamab for Large B-Cell Lymphoma in Japan
December 22, 2022
- Padcev/Keytruda Combo Accepted for FDA Review in Bladder Cancer
December 22, 2022
- Livtencity Misses PIII Goal in 1st Line Use for HSCT CMV Infection
December 21, 2022
- Eisai to Divest US Fycompa Rights to Catalyst, Focus on Alzheimer’s R&D
December 21, 2022
- Nippon Shinyaku’s JAK2 Inhibitor Earns Orphan Designation in US
December 21, 2022
- Daiichi Sankyo’s Blood Cancer Drug Ezharmia Now Available
December 21, 2022
- Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
December 21, 2022
- Chugai CEO Questions Off-Year Price Cuts for On-Patent Meds
December 21, 2022
- Janssen Japan Employees Form Labor Union to Counter Closing of Positions
December 21, 2022
- Chugai Eyes Submission of Oral GLP-1 Agent in 2025-2026: R&D Briefing
December 20, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…